Cell therapy to promote transplantation tolerance: a winning strategy?

    Research output: Contribution to journalArticlepeer-review

    18 Citations (Scopus)


    Organ transplantation is currently the only effective treatment for end-stage organ failure. However, success is limited by the immune response of the recipient to allogeneic tissues (recognized by the direct and indirect alloresponses) and by the morbidity and mortality associated with the immunosuppressive drugs that are used to control alloimmunity. One solution to these problems is the induction of immunological tolerance. In our laboratory, we have selected two strategies to achieve this goal. The first is to expand and/or generate Tregs directly in vivo using infusions of 'tolerogenic' DCs into patients; the second is to purify Tregs from the blood of patients on the waiting list for a transplant, enrich and expand these cells in vitro and then inject back in vivo after transplantation. Here, we have summarized our results both in the murine and human systems on the use of Treg-based strategies to induce tolerance to the transplanted organs.
    Original languageEnglish
    Pages (from-to)28-31
    Number of pages4
    Issue number4
    Publication statusPublished - Apr 2011


    • Animals
    • Blood Transfusion, Autologous
    • Cell Proliferation
    • Cell- and Tissue-Based Therapy
    • Clinical Trials as Topic
    • Graft Rejection
    • Humans
    • Isoantigens
    • Mice
    • Organ Transplantation
    • T-Lymphocytes, Regulatory
    • Transplantation Tolerance


    Dive into the research topics of 'Cell therapy to promote transplantation tolerance: a winning strategy?'. Together they form a unique fingerprint.

    Cite this